plerixafor has been researched along with triazoles in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hussar, DA | 1 |
| Hosoya, N; Iwamoto, A; Kawana-Tachikawa, A | 1 |
| Colby-Germinario, SP; Donahue, DA; Kramer, VG; Oliveira, M; Schader, SM; Singhroy, DN; Sloan, RD; Tressler, R; Wainberg, MA | 1 |
| Anders, M; Bozek, K; Eckhardt, M; Kaiser, R; Kräusslich, HG; Lengauer, T; Müller, B; Sierra, S | 1 |
| Biswas, P; Cozzi, P; García-Sastre, A; Ghezzi, S; Guzzo, C; Jabes, D; Lusso, P; Malnati, M; Martínez-Romero, C; Mongelli, N; Sironi, F | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Bae, E; Chen, CT; Kuan, HH; Shia, KS; Song, JS; Wang, Y; Wu, CH; Wu, KJ; Yeh, KC; Yu, SJ | 1 |
| Kong, X; Liu, X; Ma, J; Ou, C; Wang, Q; Yu, Y; Zhang, Y | 1 |
1 review(s) available for plerixafor and triazoles
| Article | Year |
|---|---|
HIV-1 tropism.
Topics: Aminoquinolines; Anti-HIV Agents; Benzimidazoles; Benzylamines; Butylamines; CCR5 Receptor Antagonists; CD4 Antigens; Cyclams; Cyclohexanes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Receptors, CCR5; Receptors, CXCR4; T-Lymphocytes; Triazoles; Viral Tropism | 2010 |
1 trial(s) available for plerixafor and triazoles
6 other study(ies) available for plerixafor and triazoles
| Article | Year |
|---|---|
New Drugs2010, PART 1.
Topics: Acetamides; Antibodies, Monoclonal; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Azepines; Benzazepines; Benzhydryl Compounds; Benzyl Alcohol; Benzylamines; Cyclams; Cyclopropanes; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Ethanolamines; Everolimus; Febuxostat; Fluorenes; Fluoroquinolones; Gout Suppressants; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Indoles; Lacosamide; Milnacipran; Oligopeptides; Phenols; Selective Serotonin Reuptake Inhibitors; Sirolimus; Tapentadol; Thiazoles; Tolvaptan; Triazoles | 2010 |
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Benzylamines; Cell Line; Cyclams; Cyclohexanes; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; RNA, Viral; Triazoles; Viral Load; Virus Internalization | 2012 |
An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
Topics: Amino Acid Sequence; Benzylamines; CCR5 Receptor Antagonists; Computational Biology; Cyclams; Cyclohexanes; Genetic Vectors; HEK293 Cells; Heterocyclic Compounds; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Models, Biological; Molecular Sequence Data; Multivariate Analysis; Phenotype; Receptors, CCR5; Receptors, CXCR4; Transfection; Triazoles; Virus Internalization | 2012 |
Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Topics: 3T3 Cells; Animals; Antiviral Agents; Benzylamines; Cell Death; Cell Line; Cyclams; Cyclohexanes; Flow Cytometry; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Membrane Fusion; Mice; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Internalization; Virus Replication | 2015 |
A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Benzylamines; Brain; Brain Infarction; Chemotaxis; Cyclams; HEK293 Cells; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Interleukin-6; Male; Mice, Inbred C57BL; Neurons; Neuroprotection; Neuroprotective Agents; Quinazolines; Rats, Sprague-Dawley; Receptors, CXCR4; Stroke; Triazoles; Tumor Necrosis Factor-alpha | 2017 |
Chemokine receptor CCR5 and CXCR4 might influence virus replication during IBDV infection.
Topics: Animals; Benzylamines; Bursa of Fabricius; CCR5 Receptor Antagonists; Cell Movement; Chickens; Cyclams; Cyclohexanes; Cytokines; Heterocyclic Compounds; Infectious bursal disease virus; Interferon-gamma; Interleukin-2; Interleukin-6; Interleukin-8; Maraviroc; Poultry Diseases; Real-Time Polymerase Chain Reaction; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR4; RNA, Messenger; T-Lymphocytes; Transcription, Genetic; Transforming Growth Factor beta; Triazoles; Viral Structural Proteins; Virus Replication | 2017 |